Evolution of the Myelodysplastic Syndromes

Tricot, Guido; Mecucci, Cristina; Berghe, Herman Van den

doi:10.1111/j.1365-2141.1986.tb07544.x

Cited by 56 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the 8;21 translocation appears not to have been reported in patients with the myelodysplastic syndrome, even when it follows a prior haematologic malignancy or cytotoxic drugs, it has been hypothesized that this karyotypic abnormality affects a late committed progenitor cell rather than one with multipotential capacity [15]. The latter suggestion has been strengthened by the demonstration of this specific cytogenetic lesion in leukaemic blasts and promyelocytes, but not in red cell precursors [ 161.…”

Section: Discussionmentioning

confidence: 98%

8;21 translocation in myelodysplasia secondary to essential thrombocythemia

1989

View full text Add to dashboard Cite

A case is presented of a 73-year-old woman who received busulphan for essential thrombocythemia and subsequently developed a myelodysplastic syndrome (MDS), which transformed to acute nonlymphoblastic leukaemia within 1 month. Cytogenetic studies showed a 46,XX,t(8;21) (q22;q22) karyotype in all metaphases examined at diagnosis. The karyotypic abnormality is previously unreported in secondary myelodysplasia and may have specific clinical implications in this setting, such as early transformation to acute leukaemia and short survival. This finding contrasts with the generally favourable prognosis of the 8;21 translocation in patients with de novo acute nonlymphoblastic leukemia. A possible explanation for this difference may be the involvement of a committed progenitor in acute nonlymphoblastic leukaemia, while in myelodysplasia the more primitive multipotent stem cell may be affected.

show abstract

Section: Discussionmentioning

confidence: 98%

8;21 translocation in myelodysplasia secondary to essential thrombocythemia

1989

View full text Add to dashboard Cite

show abstract

“…Our model of stochastic dynamics can explain this behavior. In addition, there are reports of 'spontaneous' resolution of myelodysplastic syndromes in patients [47]. Finally, the model suggests that malignant clones can experience latency and stability whereby they do not change in size appreciably.…”

Section: Stochastic Dynamics Within the Hsc Poolmentioning

confidence: 91%

Some Dynamic Aspects of Hematopoietic Stem Cells

Dingli

Pacheco

2008

Stem Cell Rev

View full text Add to dashboard Cite

Hematopoiesis is the process responsible for maintaining the number of circulating blood cells that are undergoing continuous turnover. At the root of this process are the hematopoietic stem cells (HSC). In the following we discuss various dynamic aspects of HSC behavior ranging from the number of active stem cells, their expansion during ontogeny and the importance of stochastic effects on their behavior. We show how mathematical modeling of HSC behavior can provide important insights on these cells and clarify the implications of these dynamical aspects on healthy and sick individuals, as such providing rational explanations for relevant clinical observations on disorders that originate in this group of cells.

show abstract

“…It is also occasionally observed as a prodromal syndrome preceding AML [19]. Tricot et a1 have recently suggested that the MDS and de novo AML presenting with myelody splasia are closely related disorders that arise from a pluripotent stem cell [20]. This would contrast with de novo AML without myelodysplasia (ie, t(8;21)-M2, t( 15; 17)-M3, inv( 16)-M4 and other subtypes with differentiated features) which arise from a lineage restricted progenitor cell.…”

Section: M4mentioning

confidence: 98%

Acute myelomonocytic leukemia (AML‐M4) and translocation t(6;9) (p23;q34): Two additional patients with prominent myelodysplasia

Horsman¹,

Kalousek²

1987

American J Hematol

View full text Add to dashboard Cite

Two patients with acute myelomonocytic leukemia (AML-M4) and a specific chromosomal translocation t(6;9)(p23;q34) are reported and compared to 21 AML patients with the same translocation collected from the literature. Our observation suggest that AML with t(6;9)(p23;q34) is characterized by myelodysplasia, basophilia, and a variety of blast cell morphologies (M1, M2, M4) with a greater proportion of the cases than previously appreciated being examples of acute myelomonocytic leukemia (AML-M4). The consistent association of myelodysplasia provokes the proposal that this subtype of de novo AML is a result of an acute stem cell disorder. The poor outcome with standard AML chemotherapy experienced in this group of relatively young patients necessitates consideration of alternative therapeutic strategies such as early bone marrow transplantation.

show abstract

Evolution of the Myelodysplastic Syndromes

Cited by 56 publications

References 37 publications

8;21 translocation in myelodysplasia secondary to essential thrombocythemia

8;21 translocation in myelodysplasia secondary to essential thrombocythemia

Some Dynamic Aspects of Hematopoietic Stem Cells

Acute myelomonocytic leukemia (AML‐M4) and translocation t(6;9) (p23;q34): Two additional patients with prominent myelodysplasia

Contact Info

Product

Resources

About